| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vivo |
In BALB and SHK mice, 6-methyluracil (50 mg/kg; one intraperitoneal; i.p.) has a strong radioprotective effect[2].
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Following oral administration of 6-methyl-2-thiouracil, rats excreted unchanged 6-methyl-2-thiouracil (46% of the dose), 6-methyluracil (9%), 6-methyl-2-methylthiouracil (2%), 6-methyl-4-oxouracil (2%), 2-amino-6-methyl-4-oxouracil (0.2%), and urea (1%) in their urine. …Studies have shown that 10 ppm bromopyrimidine aqueous solution, after 6 days of irradiation, produces four volatile substances. The major product (37%) is 6-methyluracil. A mixed culture of Pseudomonas and Actinomyces rubrum utilizes 6-methyluracil as the sole carbon and nitrogen source. 6-methyluracil is oxidized to uracil, which is subsequently metabolized into barbituric acid and urea. |
| Toxicity/Toxicokinetics |
Interactions
Inhalation for 5 hours daily for 4 months reduced serum albumin levels and increased serum β-globulin, γ-globulin, and β-lipoprotein levels in rats. During the inhalation period, supplementation of the rat diet with 4-methyluracil normalized lipid and protein metabolism parameters. Prophylactic use of these preparations is recommended among workers in the leather industry. |
| References | |
| Additional Infomation |
6-Methyluracil is a pyrimidinone, consisting of uracil with a methyl group attached at the 6-position. It is a metabolite functionally related to uracil.
Therapeutic Uses Anti-ulcer drug; radioprotective agent; immunoadjuvant Experimental Applications: Oral administration of 4-methyluracil (50 mg/kg/day) for 3 days before and after laparotomy to rats with lymphatic or hematogenous metastases of Prisley's lymphosarcoma or Walker's carcinosarcoma showed significant anti-metastatic effects. |
| Molecular Formula |
C5H6N2O2
|
|---|---|
| Molecular Weight |
126.11
|
| Exact Mass |
126.042
|
| CAS # |
626-48-2
|
| PubChem CID |
12283
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Melting Point |
318 °C (dec.)(lit.)
|
| Flash Point |
208ºC
|
| Index of Refraction |
1.490
|
| LogP |
-0.12
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
195
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SHVCSCWHWMSGTE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H6N2O2/c1-3-2-4(8)7-5(9)6-3/h2H,1H3,(H2,6,7,8,9)
|
| Chemical Name |
6-methyl-1H-pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (396.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.55 mg/mL (36.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.9296 mL | 39.6479 mL | 79.2959 mL | |
| 5 mM | 1.5859 mL | 7.9296 mL | 15.8592 mL | |
| 10 mM | 0.7930 mL | 3.9648 mL | 7.9296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
